Key Highlights
- H1 2026 Revenue reached $30.4 million, up from $21.5 million, aided by a $7.9 million milestone payment from Chinese partner ASK Pharm.
- ACCRUFeR US net product revenue fell to $10.3 million in Q2 from $12.8 million a year earlier despite rising prescription volumes.
- Management said the company remained profitable through H1 2026, a genuine inflection after a $22.9 million operating loss in 2024.
- Cash fell to $8.3 million at 30 June 2026 from $12.4 million at 31 March, linked to working-capital timing.
- ACCRUFeR is now the number-one branded prescription oral iron product in the US, per IQVIA data.
AIM-listed Shield Therapeutics says it stayed profitable through the first half of 2026, with revenue up sharply to $30.4m. A Chinese milestone payment flattered the numbers, and US pricing pressure on its iron-deficiency drug ACCRUFeR bears close watching.
Shield Therapeutics (LSE:STX), the AIM-listed pharmaceutical company behind the oral iron deficiency treatment ACCRUFeR, told investors on 30 July 2026 that it had remained profitable through the first half of the year, with revenue jumping to $30.4m. For a company that spent much of the past decade burning cash while it fought to get its lead drug approved and commercialised, the milestone is significant. The question for shareholders is how much of that improvement is durable US growth, and how much reflects a one-off licensing payment.
What Happened
In its Q2 and H1 2026 trading update, Shield reported group revenue of $11.9m for the second quarter, down from $14.3m a year earlier, but H1 revenue of $30.4m against $21.5m in H1 2025. The increase was driven substantially by a $7.9m development milestone payment from ASK Pharm, Shield's licensing partner for ACCRUFeR in China, Hong Kong, Macau and Taiwan. Stripped of that one-off item, underlying momentum was more mixed: ACCRUFeR US net product revenue fell to $10.3m in the quarter from $12.8m a year earlier, even as prescription volumes rose. Management said the company remained profitable during H1 2026 and reiterated it is on track for profitability across the full year, and announced that Michael Jensen will become Chief Financial Officer from 1 September 2026.
Why It Matters
Shield has long been a story of clinical and regulatory promise outpacing commercial delivery. ACCRUFeR, known as Feraccru outside the US, won FDA approval in 2019 but took years to build meaningful sales after Shield began commercialising it through a collaboration with Viatris. A first profitable half-year, even one boosted by a licensing payment, is a genuine inflection point for a Business that reported an operating loss of $22.9m as recently as 2024. It lends credibility to management's repeated promise of a "profitable, self-sustaining entity" and offers a different narrative to the cash-burn story that has dogged the stock. But the gap between headline revenue growth and underlying US product revenue is the detail investors should interrogate before taking the profitability claim at Face Value .
Latest Financial and Operational Performance
The H1 2026 update builds on a turnaround already visible in Shield's audited FY2025 results, published in April 2026. Full-year 2025 total revenue reached $49.7m, up from $32.2m in 2024, with ACCRUFeR US net product revenue of $45.8m, up 56% on 2024's $29.3m. The operating loss narrowed sharply to $10.1m from $22.9m, and cash rose to $11.6m at year-end from $6.5m a year earlier.
That progress continued into 2026, but cash generation in the first half was less clear-cut. Cash fell to $8.3m at 30 June 2026 from $12.4m at 31 March, a decline management attributed to working Capital and cost-management timing rather than underlying weakness. Shield operates under a senior secured Debt Facility of up to $50m, provided by SWK Holdings Corporation and Runway Growth Finance Corp, maturing in September 2028. The facility was amended in December 2025 on more favourable terms, reflecting lenders' improved view of the business as ACCRUFeR sales scaled.
Average net price per prescription fell to $208 in Q2 2026 from $231 a year earlier, which management linked to prior authorisation requirements in New York's Medicaid programme, prompting a shift towards commercial payer channels. Prescription volumes nonetheless grew: roughly 49,000 in Q2 2026 versus 47,000 a year earlier, and around 102,000 across H1 2026, up 21%.
Key Numbers
- H1 2026 total revenue: $30.4m (H1 2025: $21.5m)
- Q2 2026 revenue: $11.9m (Q2 2025: $14.3m); ACCRUFeR net revenue $10.3m (Q2 2025: $12.8m)
- $7.9m development milestone received from Chinese partner ASK Pharm
- FY2025 total revenue: $49.7m (2024: $32.2m); ACCRUFeR US net revenue $45.8m (2024: $29.3m)
- FY2025 operating loss: $10.1m (2024: $22.9m)
- Cash at 30 June 2026: $8.3m (31 March 2026: $12.4m; 31 December 2025: $11.6m)
- H1 2026 prescriptions dispensed: approximately 102,000, up 21% year-on-year
- Average ACCRUFeR net price, Q2 2026: $208 (Q2 2025: $231)
- Debt facility: up to $50m with SWK Holdings and Runway Growth Finance, maturing September 2028
Growth Opportunities
Shield says ACCRUFeR is now the number-one branded prescription oral iron product in the US, citing IQVIA data, in a market it estimates at $2.3bn covering around 20 million Americans with iron deficiency. It signed its first Group Purchasing Organisation contract during the period, opening access to more than 400 clinics. Internationally, Chinese partner ASK Pharm has an MAA submission under review by the National Medical Products Administration, the EMA extended approval to adolescent patients in March 2026, and a Phase 3 paediatric trial was published in July 2026, potentially widening the eligible patient population. Licensing deals covering Japan, South Korea and the UK/EU provide further optionality without Shield having to fund commercialisation itself.
Risks Investors Should Know
The most immediate concern is the gap between headline revenue growth and underlying US trends: quarterly ACCRUFeR net revenue actually declined year-on-year, with falling net pricing linked to Medicaid reimbursement friction in New York. Cash fell by roughly a third in a single quarter, and investors should watch whether that pattern persists. Shield remains reliant on a single approved product and on Viatris for US commercial execution, concentrating risk. It also carries secured debt with Warrant and fee obligations that could dilute or constrain the business if profitability targets slip. As with any small-cap pharmaceutical stock, forward-looking guidance is inherently uncertain.
What to Watch Next
Investors should watch the next trading update and full-year results for confirmation that profitability materialises as guided and that cash stabilises. The transition to new CFO Michael Jensen from September 2026 will test financial discipline. Progress converting the GPO contract into prescription Volume , clarity from ASK Pharm on China's regulatory timeline, and any further US pricing developments will also shape sentiment.
Outlook
Shield Therapeutics (LSE:STX) has genuine cause for optimism after years of losses, with a first profitable half-year and a stronger Balance Sheet than a year ago. Yet the H1 2026 figures also show revenue growth was flattered by a one-off milestone payment while US product sales faced pricing pressure. Whether 2026 delivers sustainable, self-funded profitability, rather than a headline number dependent on licensing income, will decide the stock's trajectory through the rest of the year.


_11_18_2026_06_43_20_247880.jpg)



Please wait processing your request...